Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease
- 1 December 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 33 (12), 2902-2908
- https://doi.org/10.1161/atvbaha.113.302479
Abstract
Objective—: Association between lipoprotein(a) (Lp(a)) level and a first-ever coronary (CHD) event is recognized. Less is evident in patients with overt CHD and stable symptoms in whom we investigated associations between Lp(a) and future events. Approach and Results—: Relationships between Lp(a) concentration and CHD and cardiovascular disease outcomes during 6 years’ median follow-up were evaluated in the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. Lp(a) concentrations were measured in plasma from 7863 patients who had sustained a previous coronary event and been randomized to pravastatin or placebo. Lp(a) levels were categorized by lowest half, third quartile, 75th to 90th percentile, and highest decile. The prognostic value of Lp(a) on outcomes was assessed by fitting a Cox proportional-hazards model after adjustment for other risk factors and baseline cardiovascular disorders. The prognostic value of a change in Lp(a) at year 1 categorized by quartiles was assessed using Cox regression in a landmark model incorporating the above factors and baseline levels. Baseline Lp(a) concentration was associated with total CHD events ( P 73 mg/dL, upper decile. For events after year 1, an increase in Lp(a) at 1 year was associated with adverse outcomes for total CHD events and total cardiovascular disease events ( P =0.002 each). Conclusions—: In the LIPID study, baseline Lp(a) was associated with future cardiovascular disease and CHD events. Increased Lp(a) concentrations after 1 year were also associated with future events, supporting measurement of Lp(a) for risk assessment of patients with known CHD.Keywords
This publication has 32 references indexed in Scilit:
- Mechanisms of Lipoprotein(a) PathogenicityArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White SubjectsCirculation, 2012
- Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring StudyJournal of Lipid Research, 2011
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapyJournal of Lipid Research, 2010
- Lipoprotein(a) and Risk of Type 2 DiabetesClinical Chemistry, 2010
- Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Increased Degradation of Lipoprotein(a) in Atherosclerotic Compared With Nonlesioned Aortic Intima–Inner Media of RabbitsArteriosclerosis, Thrombosis, and Vascular Biology, 1998